Skip to content

Metallization based therapy for adults with ADHD

Metallization based therapy for adults with ADHD - MBT-ADHD

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00031549
Enrollment
24
Registered
2023-06-19
Start date
2023-03-22
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F90.0

Interventions

Group 1: MBT-ADHD with prior psychoeducation for all patients The pilot study MBT-ADHD evaluates mentalization based group therapy for adults with ADHD, comprising of 12 sessions psychoeducation on

Sponsors

IPU Hochschulambulanz
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: All adults between the ages of 18 and 70 who have an ADHD diagnosis confirmed by us and are not already undergoing psychotherapeutic treatment can participate. There must be consent to videotape diagnostic and therapeutic sessions for scientific purposes.

Exclusion criteria

Exclusion criteria: Adults who are in ongoing individual or group psychotherapy or have a diagnosed personality disorder, psychosis, or addiction (alcohol, drugs, other substances) cannot attend.

Design outcomes

Primary

MeasureTime frame
Emotionregulation (DERS-SF, CERQ, FFMQ) Mentalizing (CAMSQ, RFQ8, ETMCQ) ADHD-Symptoms (DIVA-5, d2-R, ASRS, AAQoL, SCL-K-9, PHQ-D, WURS-K) Measurement points are: before treatment: baseline (T0), further measurement points are after 3, 6, 9 und 12 months (T1-T4), after end of treatment (T5). A 12 month follow-up (T6) is intended

Secondary

MeasureTime frame
Personality Functioning (SEFP-S, OPD-SFK, PID-5-BF) Komorbidities (STAI, BDI-II) Metacognitive processes (FFMQ) Body awareness (MAIA) Group cohesion (GQ-D) Childhood traumatic experiences (CTQ, ACE-D) Life Quality (SWSL, AAQoL)

Countries

Germany, Switzerland

Contacts

Public ContactLenka Staun

IPU

lenka.staun@ipu-berlin.de+4930300117800

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026